These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36739399)

  • 1. MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series.
    Mauceri R; Coppini M; Attanasio M; Bedogni A; Bettini G; Fusco V; Giudice A; Graziani F; Marcianò A; Nisi M; Isola G; Leonardi RM; Oteri G; Toro C; Campisi G
    BMC Oral Health; 2023 Feb; 23(1):71. PubMed ID: 36739399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
    Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
    Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?
    Ueda N; Nakashima C; Aoki K; Shimotsuji H; Nakaue K; Yoshioka H; Kurokawa S; Imai Y; Kirita T
    Clin Oral Investig; 2021 May; 25(5):3087-3093. PubMed ID: 33057886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical status of established MRONJ in oncology patients continuing bone-modifying agents.
    Miles E; Arya R; Sproat C; Patel V
    Br Dent J; 2024 May; 236(9):683-687. PubMed ID: 38730156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
    Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
    Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw.
    Yarom N; Van Poznak CH; Epstein JB; Ottaviani G; Matsuda Y; Migliorati C; Elad S
    Support Care Cancer; 2024 Jul; 32(8):547. PubMed ID: 39048887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
    Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
    Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of bone loss due to endocrine therapy during cancer treatment.
    Khan MI
    Osteoporos Int; 2023 Apr; 34(4):671-680. PubMed ID: 36656338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How we manage medication-related osteonecrosis of the jaw.
    Byrne H; O'Reilly S; Weadick CS; Brady P; Ríordáin RN
    Eur J Med Res; 2024 Aug; 29(1):402. PubMed ID: 39095845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer.
    Ueda N; Aoki K; Shimotsuji H; Nakashima C; Kawakami M; Imai Y; Kirita T
    J Bone Miner Metab; 2021 Jul; 39(4):623-630. PubMed ID: 33420576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
    Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
    PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects.
    Fusco V; Di Maio M; Valsecchi AA; Santini D; Tucci M; De Giorgi U; Bossi P; Ibrahim T; Cavanna L; Lanzetta G; Rossi M; Rossetti G; Airoldi M; Comandone A; Cinieri S
    Support Care Cancer; 2024 Mar; 32(3):202. PubMed ID: 38427111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis?
    Giovannacci I; Meleti M; Manfredi M; Mortellaro C; Greco Lucchina A; Bonanini M; Vescovi P
    J Craniofac Surg; 2016 May; 27(3):697-701. PubMed ID: 27092912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.
    Drudge-Coates L; Van den Wyngaert T; Schiødt M; van Muilekom HAM; Demonty G; Otto S
    Support Care Cancer; 2020 Sep; 28(9):4019-4029. PubMed ID: 32307659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentoxifylline and tocopherol as prophylaxis for osteonecrosis of the jaw due to bone-modifying agents in patients with cancer submitted to tooth extraction: a case series.
    Magalhães JMI; da Motta Silveira FM; Regueira LS; de Lima E Silva DF; de Andrade Veras SR; de Mello MJG
    Support Care Cancer; 2023 Jul; 31(8):462. PubMed ID: 37436539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.
    Hallmer F; Bjarnadottir O; Götrick B; Malmström P; Andersson G
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Sep; 130(3):252-257. PubMed ID: 32536575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pain characteristics in medication-related osteonecrosis of the jaws.
    Haviv Y; Geller Z; Mazor S; Sharav Y; Keshet N; Zadik Y
    Support Care Cancer; 2021 Feb; 29(2):1073-1080. PubMed ID: 32601851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients.
    Soutome S; Otsuru M; Hayashida S; Murata M; Yanamoto S; Sawada S; Kojima Y; Funahara M; Iwai H; Umeda M; Saito T
    Sci Rep; 2021 Aug; 11(1):17226. PubMed ID: 34446755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.